Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
A Japanese health ministry panel will meet on October 21 to discuss a string of label expansions, including for Nippon Boehringer Ingelheim’s HER2 tyrosine kinase inhibitor Hernexeos (zongertinib) and AbbVie’s JAK inhibitor Rinvoq (upadacitinib). The Pharmaceutical Affairs Council’s Second Committee…
To read the full story
Related Article
- Hernexeos, Rinvoq, Tukysa Label Expansions Now in Line for Japan Approval
October 22, 2026
- Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
April 9, 2026
- Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
March 23, 2026
- Stella Pharma Files Steboronine for Recurrent Meningioma
March 18, 2026
- Servier Japan Seeks First-Line Pancreatic Cancer Use for Onivyde
December 17, 2025
- AbbVie Japan Seeks Rinvoq’s Broader Label for Alopecia Areata
December 16, 2025
- Meiji Seeks Label Expansion for Laserphyrin in Cervical Intraepithelial Neoplasia
November 28, 2025
REGULATORY
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026
- MHLW Drug Supply Monitoring System Hit by Cyberattack, Possible Data Leak
November 19, 2026
- Japan’s FY2027 AMED Budget Requests Top 450 Billion Yen
November 19, 2026





